Several IL-17 inhibitors are currently approved for clinical use:
- Secukinumab: A monoclonal antibody that targets IL-17A. - Ixekizumab: Another monoclonal antibody that specifically binds to IL-17A. - Brodalumab: A monoclonal antibody that targets the IL-17 receptor A, thereby blocking the activity of multiple IL-17 family cytokines.